← Eichor
Condition: Bcg Vaccine Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Bcg Vaccine

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Pa
Phase 2 · 16 location(s) · Theralase® Technologies Inc. · NCT03945162Antibiotics and Vaccine Immune Responses Study
Phase 4 · 1 location(s) · South Australian Health and Medical Research Institute · NCT06148025A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unr
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07424287Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Phase 2 · 7 location(s) · CHU de Quebec-Universite Laval · NCT05327647A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Phase 1/Phase 2 · 20 location(s) · SURGE Therapeutics · NCT05710848A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT05410730Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Phase 2 · 1 location(s) · Changhai Hospital · NCT07307456A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Phase 2 · 89 location(s) · Merck Sharp & Dohme LLC · NCT06833073A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasiv
Phase 3 · 110 location(s) · Janssen Research & Development, LLC · NCT06919965A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
Phase 2 · 2 location(s) · ImmVira Pharma Co. Ltd · NCT06971614Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Gue
Phase 2 · 14 location(s) · Lepu Biopharma Co., Ltd. · NCT07283835Predicting BCG Response
Phase N/A · 6 location(s) · Cedars-Sinai Medical Center · NCT04564781Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Phase N/A · 1 location(s) · Johns Hopkins University · NCT05672615A Phase I Intravesical PPM Therapy for NMIBC
Phase 1 · 1 location(s) · VA Office of Research and Development · NCT05519241DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 · 1 location(s) · Fudan University · NCT07207824Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)
Phase 2 · 1 location(s) · University of Virginia · NCT07094711A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (
Phase 1 · 3 location(s) · Ractigen Therapeutics. · NCT06351904A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Phase 1/Phase 2 · 12 location(s) · Suzhou Forlong Biotechnology Co., Ltd · NCT07122414Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive B
Phase 3 · 6 location(s) · Verity Pharmaceuticals Inc. · NCT05037279Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
Phase 2 · 1 location(s) · S. Andrea Hospital · NCT03888924LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Phase 1/Phase 2 · 102 location(s) · enGene, Inc. · NCT04752722Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Partici
Phase 3 · 6 location(s) · Protara Therapeutics · NCT07480356Early vs Delayed Intravesical Blad-Care During BCG Therapy
NA · 1 location(s) · BLAD-HYA Group · NCT07495072A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in
Phase 3 · 76 location(s) · Ferring Pharmaceuticals · NCT06545955Measles and BCG Vaccines for Mother and Child
Phase 4 · 1 location(s) · Bandim Health Project · NCT04899765A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Phase 1/Phase 2 · 15 location(s) · Merck Sharp & Dohme LLC · NCT07222488Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recu
Phase 3 · 1 location(s) · Chengdu CoenBiotech Co., Ltd · NCT06241755Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Tre
Phase 4 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07474519Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Inva
Phase 3 · 58 location(s) · Alliance for Clinical Trials in Oncology · NCT07000084
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.